Wu YF, Wang T, Yue ZD, Zhao HW, Wang L, Fan ZH, He FL, Liu FQ. Stents combined with iodine-125 implantation to treat main portal vein tumor thrombus. World J Gastrointest Oncol 2018; 10(12): 496-504 [PMID: 30595803 DOI: 10.4251/wjgo.v10.i12.496]
Corresponding Author of This Article
Fu-Quan Liu, MD, Professor, De¬partment of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, No. 10, Tie Yi Road, Haidian District, Beijing 100038, China. liufq_sjt@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Dec 15, 2018; 10(12): 496-504 Published online Dec 15, 2018. doi: 10.4251/wjgo.v10.i12.496
Table 1 Baseline characteristics, n (%)
Group A (n = 54)
Group B (n = 57)
P value
Gender
0.693
Male
35 (64.8)
39 (68.4)
Female
19 (35.2)
18 (31.6)
Average age (yr)
43.6 ± 6.9
44.3 ± 5.2
0.697
Pathogenesis
0.788
Hepatitis B
35 (64.8)
38 (66.7)
Hepatitis C
9 (16.7)
12 (21)
Alcoholic
5 (9.3)
2 (3.5)
Cholestasis
2 (3.7)
1 (1.8)
Autoimmunity
1 (1.8)
2 (3.5)
Others
2 (3.7)
2 (3.5)
Child–Pugh classification
0.705
A
25 (46.3)
24 (42.1)
B
29 (53.7)
33 (57.9)
C
0 (0)
0 (0)
Albumin (g/L)
34.5 ± 7.5
31.5 ± 11.5
0.880
Alanine aminotransferase (U/L)
62.5 ± 46.5
49.5 ± 37.5
0.396
Glutamyl transpeptidase (U/L)
73 ± 66
74 ± 62
0.647
Na+
143.5 ± 8.5
140 ± 7
0.104
K+
4.12 ± 1.08
4.75 ± 1.05
0.883
Direct bilirubin (μmol/L)
29.8 ± 25.2
24.5 ± 18.5
0.299
Aspartate aminotransferase (U/L)
39 ± 30
49 ± 39
0.349
MELD score
11.96 ± 1.68
12.76 ± 2.47
0.145
Ascites
0.624
Yes
11 (20.4)
9 (15.8)
No
43 (79.6)
48 (84.2)
Size of liver cancer (cm)
0.788
≤ 5
14 (25.9)
17 (29.8)
5-8
31 (57.4)
29 (50.9)
> 8
9 (16.7)
11 (19.3)
No. of liver tumors
0.834
1
28 (51.9)
32 (56.1)
2 or 3
19 (35.2)
17 (29.8)
> 3
7 (12.9)
8 (14.1)
Table 2 Differences of portosystemic pressure gradient in the two groups before and after operation
PPG before operation (mmHg)
PPG after operation (mmHg)
t
df
P value
Group A
26.9 ± 6.22
13.6 ± 6.4
18.11
53
< 0.0001
Group B
26.77 ± 6.25
15.1 ± 7.2
17.10
56
< 0.0001
Table 3 Time-to-event outcomes
Group A (n = 54)
Group B (n = 57)
P value
Rate of stent stenosis
< 0.05
6 mo
18.5
43.9
12 mo
55.6
82.5
24 mo
83.3
96.5
Survival rate
< 0.05
6 mo
85.2
50.9
12 mo
42.6
10.5
24 mo
22.2
0
Table 4 Multivariate analysis of factors associated with postoperative outcomes
Hazard ratio
95%CI
P value
Pathogenesis
1.227
0.773–1.948
0.385
Albumin (g/L)
1.266
0.829–1.932
0.275
Alanine aminotransferase (U/L)
1.222
0.798–1.872
0.357
Glutamyl transpeptidase (U/L)
0.821
0.509–1.224
0.419
Direct bilirubin (μmol/L)
2.262
0.270–18.96
0.452
Aspartate aminotransferase (U/L)
1.270
0.800–2.017
0.311
No. of liver tumors
1.238
0.232–19.41
0.330
Citation: Wu YF, Wang T, Yue ZD, Zhao HW, Wang L, Fan ZH, He FL, Liu FQ. Stents combined with iodine-125 implantation to treat main portal vein tumor thrombus. World J Gastrointest Oncol 2018; 10(12): 496-504